AMATERAS study (AMATERAS study)

Recruiting

• Conditions: Unresectable advanced/recurrent colorectal cancer

• Registration Number: jRCTs041240051

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-06-26
• Study Start: 2024-08-14
• Last Update Posted: 2025-05-09

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 88

Inclusion Criteria

1. Participants must have received at least 2 prior systemic therapies in adjuvant and/or metastatic setting (progressed on at least 1 prior regimen in the metastatic setting) or could not tolerate standard treatment
2. Age >= 20 years at the time of informed consent
3. Written informed consent
4. CRP >0.5 mg/dL confirmed on 2 consecutive visits in the past 2 months before enrollment
5. ECOG Performance Status of 0-2
6. Expected to be followed up for >= 12 weeks from enrollment

Exclusion Criteria

1. Patients with MSI-High or TMB-High colorectal cancer who are or have been treated with immune checkpoint inhibitors as usual therapy
2. Complications affecting nutrition and inflammation, such as chronic renal dysfunction and autoimmune diseases
3. Patients with infectious diseases requiring antibiotic therapy
4. Ileostomy/colostomy patients with diarrhea that interferes with daily life
5. Patients with a surgery in the past 4 weeks from enrollment, or scheduled a surgery during the study period
6. History of gastrectomy
7. Taking kampo medicine in the previous 2 weeks from visit1 of the study period
8. Inable of oral food intake, due to obstruction/other organic abnormality of the gastrointestinal tract or dysphagia.
9. Inable of taking kampo medicines
10. Moderate or severe hepatic dysfunction (Child-Pugh classification B and C)
11. Patients with any following factors in the past 2 months before enrollment -1 AST, ALT,GGTP : each items > 5 times the facility standard -2 T-bil, Cr : each items > 3 times the facility standard -3 K : K < 3.0 mmol/L or K > 5.5 mmol/L
12. Pleural or ascitic effusion
13. Synchronous or metachronous malignancies
14. Severe complications (cardiac, hematological or metabolic diseases, etc.)
15. History of severe drug hypersensitivity or allergy (especially to Hochuekkito)
16. Pregnant, lactating, possibly pregnancy or patients who plan to getting pregnancy during the study period
17. Judged as ineligible by investigators

Study & Design

• Study Type: Interventional
• Study Design: parallel assignment

Primary Outcome Measures

Name	Time	Method
CRP change rate	at the start of treatment and after 12 weeks	The anti-inflammatory effects of group A and group B are compared by the CRP change rate

Secondary Outcome Measures

Name	Time	Method
The effects of Hochuekkito in combination with other appetite stimulants and nutrient		The effects of Hochuekkito in combination with other appetite stimulants and nutrient
The effects of Hochuekkito on anti-tumor and adverse anticancer drug reactions		The effects of Hochuekkito on anti-tumor and adverse anticancer drug reactions
The effects of Hochuekkito on inflammatory and nutritional states		The effects of Hochuekkito on inflammatory and nutritional states
The effects of Hochuekkito on QOL score		The effects of Hochuekkito on QOL score
The anti-inflammatory and anti-cachexia effects of Hochuekkito at the cytokine level		The anti-inflammatory and anti-cachexia effects of Hochuekkito at the cytokine level